MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

February 28, 2017

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

MABp1

This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal

DRUG

Placebo

The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.

Trial Locations (1)

12462

4th Department of Internal Medicine, ATTIKON University Hospital, Athens

All Listed Sponsors
collaborator

Hellenic Institute for the Study of Sepsis

OTHER

lead

Evangelos J. Giamarellos-Bourboulis, M.D.

OTHER

NCT02643654 - MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB | Biotech Hunter | Biotech Hunter